Brokerages Set Microbot Medical Inc. (NASDAQ:MBOT) Price Target at $6.63

Microbot Medical Inc. (NASDAQ:MBOT) has received a consensus rating of “Moderate Buy” from the five ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $6.6250.

Several analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Microbot Medical in a research report on Friday, April 10th. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Microbot Medical in a research report on Tuesday, April 14th. Finally, Loop Capital set a $4.00 target price on shares of Microbot Medical in a research report on Wednesday, June 3rd.

Institutional Trading of Microbot Medical

Institutional investors have recently made changes to their positions in the business. CIBC Private Wealth Group LLC boosted its position in Microbot Medical by 137.6% in the third quarter. CIBC Private Wealth Group LLC now owns 1,454,000 shares of the biotechnology company’s stock valued at $4,435,000 after buying an additional 842,000 shares in the last quarter. Heights Capital Management Inc. acquired a new position in Microbot Medical in the third quarter valued at about $2,693,000. DNB Asset Management AS boosted its position in Microbot Medical by 178.1% in the fourth quarter. DNB Asset Management AS now owns 677,498 shares of the biotechnology company’s stock valued at $1,355,000 after buying an additional 433,869 shares in the last quarter. Cornerstone Advisory LLC acquired a new position in Microbot Medical in the third quarter valued at about $30,000. Finally, Squarepoint Ops LLC lifted its position in shares of Microbot Medical by 102.6% during the fourth quarter. Squarepoint Ops LLC now owns 24,526 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 12,419 shares in the last quarter. 16.30% of the stock is currently owned by institutional investors and hedge funds.

Microbot Medical Stock Performance

NASDAQ:MBOT opened at $1.86 on Monday. The firm’s 50-day moving average is $2.02 and its 200-day moving average is $2.16. Microbot Medical has a 52-week low of $1.60 and a 52-week high of $4.67. The company has a debt-to-equity ratio of 0.01, a quick ratio of 21.93 and a current ratio of 22.59. The company has a market cap of $124.94 million, a price-to-earnings ratio of -7.15 and a beta of 1.04.

Microbot Medical (NASDAQ:MBOT) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.30 million. Equities research analysts anticipate that Microbot Medical will post -0.31 earnings per share for the current year.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.